Back to results
US 7,740,845 B2Granted
Uses of monoclonal antibody 8H9
AssigneeSloan-Kettering Institute for Cancer Research
InventorNai-Kong V. Cheung
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSloan-Kettering Institute for Cancer Research
InventorNai-Kong V. Cheung
Estimating the term…
This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.
A method of inhibiting the growth of tumor cells comprising contacting said tumor cells with a polypeptide comprising a single chain variable fragment (scFv) of monoclonal antibody 8H9, wherein the scFv comprises the amino acid sequence of SEQ ID NO. 40.
A method of inhibiting the growth of tumor cells in a subject comprising administering to the subject a polypeptide comprising a single chain variable fragment (scFv) derived from monoclonal antibody 8H9, wherein the scFv comprises the amino acid sequence of SEQ ID NO.40.
Dependencies are inferred from the claim text.